OraSure Technologies (OSUR) was Downgraded by Raymond James to ” Mkt Perform”. Earlier the firm had a rating of “Outperform ” on the company shares. Raymond James advised their investors in a research report released on Jun 13, 2016.
On the company’s financial health, OraSure Technologies reported $0.04 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on May 4, 2016. Analyst had a consensus of $0.02. The company had revenue of $29.10 million for the quarter, compared to analysts expectations of $28.82 million. The company’s revenue was up 7.4% compared to the same quarter last year.
OraSure Technologies closed down -0.125 points or -1.58% at $7.78 with 3,06,387 shares getting traded on Friday. Post opening the session at $7.84, the shares hit an intraday low of $7.72 and an intraday high of $7.89 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
OraSure Technologies Inc. (OraSure) is involved in the development manufacture marketing and sale of oral fluid diagnostic products and specimen collection devices and other diagnostic products designed to detect or diagnose critical medical conditions. These products include OraQuick In-Home HIV Test OraQuick ADVANCE OraSure HIV-1 oral specimen collection device OraQuick HCV rapid antibody test Intercept oral fluid drug testing system OraSure QuickFlu Rapid Flu A&B Test and Q.E.D. Saliva Alcohol test. The Company also manufactures and sells a range of cryosurgical products. Through its wholly owned subsidiary DNA Genotek Inc. the Company provides oral fluid sample collection stabilization and preparation products for molecular diagnostic applications.